
    
      In this phase II, open, single arm study, it will be evaluated of the efficacy and safety of
      erlotinib in 2nd/3rd line of EGFR WT and c-Met negative advanced NSCLC.The treatment goes as
      follows:Erlotinib 150mg/day taken orally until disease progression or intolerable
      toxicities.The primary end point of the study was 6 months PFS rate.
    
  